Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bioage Labs Inc (BIOA)

Bioage Labs Inc (BIOA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 416,276
  • Shares Outstanding, K 35,855
  • Annual Sales, $ 0 K
  • Annual Income, $ -71,110 K
  • EBIT $ -90 M
  • EBITDA $ -90 M
  • 60-Month Beta 1.74
  • Price/Sales 70.42
  • Price/Cash Flow N/A
  • Price/Book 1.36

Options Overview Details

View History
  • Implied Volatility 141.64% (+27.87%)
  • Historical Volatility 68.78%
  • IV Percentile 18%
  • IV Rank 11.77%
  • IV High 826.12% on 04/04/25
  • IV Low 50.29% on 09/17/25
  • Expected Move (DTE 12) 0.60 (5.12%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 203
  • Volume Avg (30-Day) 77
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 1,555
  • Open Int (30-Day) 3,085
  • Expected Range 11.02 to 12.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.01
  • Number of Estimates 2
  • High Estimate -0.75
  • Low Estimate -1.27
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.75 +72.00%
on 11/07/25
11.63 -0.17%
on 12/05/25
+4.11 (+54.80%)
since 11/05/25
3-Month
4.68 +148.08%
on 09/16/25
11.63 -0.17%
on 12/05/25
+6.85 (+143.91%)
since 09/05/25
52-Week
2.88 +303.12%
on 04/09/25
20.37 -43.00%
on 12/06/24
-6.76 (-36.80%)
since 12/05/24

Most Recent Stories

More News
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β,...

BIOA : 11.61 (+10.57%)
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for...

BIOA : 11.61 (+10.57%)
BioAge Labs to Present at Jefferies Global Healthcare Conference in London

EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for...

BIOA : 11.61 (+10.57%)
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates

First participant dosed in Phase 1 trial of BGE-102, oral CNS-penetrant NLRP3 inhibitor, with initial SAD data expected by year-end Continued advancement of oral and parenteral APJ agonist programs...

BIOA : 11.61 (+10.57%)
BioAge Labs to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for...

BIOA : 11.61 (+10.57%)
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile Initial development...

BIOA : 11.61 (+10.57%)
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates

Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline through option agreement for novel antibody and advancement...

BIOA : 11.61 (+10.57%)
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

BIOA : 11.61 (+10.57%)
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank

BIOA : 11.61 (+10.57%)
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates

BIOA : 11.61 (+10.57%)

Business Summary

BioAge Labs Inc. is a clinical-stage biopharmaceutical company. It involved in developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of aging. BioAge Labs Inc. is based in RICHMOND, Calif.

See More

Key Turning Points

3rd Resistance Point 13.48
2nd Resistance Point 12.55
1st Resistance Point 12.08
Last Price 11.61
1st Support Level 10.69
2nd Support Level 9.76
3rd Support Level 9.29

See More

52-Week High 20.37
Fibonacci 61.8% 13.69
Fibonacci 50% 11.63
Last Price 11.61
Fibonacci 38.2% 9.56
52-Week Low 2.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar